CNS Pharma (NASDAQ:CNSP) Stock, Quote.Headers.trade-ideas

CNS Pharmaceuticals

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGRI

ATNM

ATPC

BJDX

CHGG

CNSP

HPAI

LCID

LUMN

PLTR

RXST

SERV

SMFG

SPWR

TENK

TPET

UPXI

Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket

Kellanova

AIXI

APLD

AQMS

CIFR

CLSK

FFIN

INDO

IREN

MGOL

MIRA

MSTR

RSKD

WULF

XXII

ZVRA

Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Headquarters_Rahway-Site-Entrance_HI

Intraday Update

AMKR

BIMI

BLMZ

CALC

CLDX

CRWD

CVLT

EKSO

ENVB

FFIV

HAYW

HLIT

IMNN

INVO

ISPO

JBLU

JTAI

LSCC

MBIN

NIPG

NVAX

ONEW

PCSA

PHAR

PYPL

RGEN

RMBS

SMRT

TLRY

TRNS

TWOU

VBIV

VRNS

VSEE

Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

CNS Pharmaceuticals Inc

<a href="https://www.meta.com/connect/" title="https://www.meta.com/connect/">https://www.meta.com/connect/</a>

Events

Meta Connect 2024 Kicks Off September 25-26, Featuring Keynote From Mark Zuckerberg Focused On XR Platforms, Metaverse, And Generative AI, With Possible Unveiling Of Meta Quest 4 And AR Hardware Updates

Cantor Fitzgerald analyst Andres Sheppard reiterates VinFast Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) with a Overweight and maintains $6 price target.

Price Target

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on VinFast Auto, Maintains $6 Price Target

Citigroup analyst Thomas Palmer maintains Lamb Weston Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) with a Buy and raises the price target from $72 to $75.

Citigroup Maintains Buy on Lamb Weston Hldgs, Raises Price Target to $75

Denny's Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DENN#NASDAQ">DENN</a>) today announced two key leadership appointments aimed at advancing the company's technological innovation and operational growth. Minh Le has been named senior vice president and chief technology officer, effective September 23, and Christopher Bode will return as president and chief operating officer, effective September 30. These appointments reflect Denny's ongoing commitment to enhancing its technological infrastructure and operational excellence across the brand.
Minh Le, a respected leader in restaurant technology, will serve as senior vice president and chief technology officer for Denny's Corporation. In this role, he will oversee the entire technology ecosystem across both Denny's and Keke's Breakfast Café, with a focus on modernizing and integrating innovative solutions to enhance guest experiences, improving operational efficiencies, and ensuring data security and compliance. Le brings over 25 years of experience in steering large-scale technology transformations for major restaurant brands, including Checkers &amp; Rally's Drive-In Restaurants, CBC Restaurants, Romano's Macaroni Grill, and Darden Restaurants.

Management

DENN

Denny's Announces Key Leadership Appointments, Naming Minh Le As CTO And Christopher Bode As President And COO To Drive Innovation And Operational Growth

Cantor Fitzgerald analyst Andres Sheppard reiterates Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) with a Overweight and maintains $7 price target.

RKLB

Cantor Fitzgerald Reiterates Overweight on Rocket Lab USA, Maintains $7 Price Target

Citigroup analyst Kyle Menges maintains Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) with a Neutral and lowers the price target from $60 to $57.

Citigroup Maintains Neutral on Terex, Lowers Price Target to $57

Cantor Fitzgerald analyst Andres Sheppard reiterates Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) with a Overweight and maintains $19 price target.

RIVN

Cantor Fitzgerald Reiterates Overweight on Rivian Automotive, Maintains $19 Price Target

Macro Economic Events

Global

Economics

German Economy Minister Says A Big Part Of The Auto Market Problem Lies In Demand From China, It Doesn't Seem That This Problem Will Be Solved Soon

Cantor Fitzgerald analyst Andres Sheppard reiterates Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) with a Overweight and maintains $6 price target.

Cantor Fitzgerald Reiterates Overweight on Redwire, Maintains $6 Price Target

Cantor Fitzgerald analyst Andres Sheppard reiterates Polestar Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) with a Overweight and maintains $3 price target.

PSNY

Cantor Fitzgerald Reiterates Overweight on Polestar Automotive, Maintains $3 Price Target

GPUS

Hyperscale Data Shares Resume Trade

Contracts

TotalEnergies CEO Says In Talks With Brazil's Petrobras For Potential Joint Businesses Abroad

Cantor Fitzgerald analyst Andres Sheppard reiterates Ouster (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) with a Neutral and maintains $12 price target.

OUST

Cantor Fitzgerald Reiterates Neutral on Ouster, Maintains $12 Price Target

Barclays analyst Balaji Prasad maintains Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) with a Overweight and raises the price target from $21 to $22.

ELAN

Barclays Maintains Overweight on Elanco Animal Health, Raises Price Target to $22

Winnebago Industries Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) shares are facing selling pressure Monday after a short selling firm suggested cracks are <a href="https://www.benzinga.com/quote/WGO">starting to show at Winnebago</a>.
What To Know: Hunterbrook published a <a href="https://hntrbrk.com/winnebago/">report</a> Monday morning claiming Winnebago's best-selling Grand Design RV, which accounts for about 35% of the company&#8217;s total revenue, appears to be experiencing &#8220;widespread frame failure.&#8221;
Hunterbrook highlighted multiple customers who have publicly posted about frame failure and suggested that Winnebago is aware of the defects and may be trying to hide the problems through non-disclosure agreements, buybacks and online censorship of complaints. 
The report said there is mounting pressure on <a href="https://www.benzinga.com/quote/WGO">Winnebago</a> to issue a recall due to frame problems as legal and industry experts reportedly told Hunterbrook that a recall is &#8220;overdue.&#8221; The firm also claims that a certified welder and retired structural stress analysis engineer said that all of the Grand Design RVs he inspected on a recent trip had broken frames.
Benzinga has reached out to Winnebago for comment on the report. 
Hunterbrook said Winnebago is losing customers, noting that Grand Design&#8217;s fifth wheels have lost 20% market share since 2023, while Grand Design&#8217;s travel trailers have lost about 13% share over the same period of time based on the firm&#8217;s analysis.
Grand Design inventory levels are rising, according to the report. Hunterbrook said the company&#8217;s share of inventory at major dealerships is up more than 100% since mid-September.
Lawsuits are also starting to pile up. The report states that customers have sued Winnebago more than 15 times in recent years related to warranty claims. Warranty claims paid by Winnebago reportedly jumped 278% from 2017 to 2023. 
Hunterbrook also pointed to the departure of company executives as a worrying sign. Hunterbrook claims at least 20 key executives have left Winnebago&#8217;s Grand Design unit for competitor Brinkley RV since 2021. 
Check This Out: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40983043/us-services-growth-tops-estimate-contraction-in-manufacturing-worsens-reacceleratio">US Services Growth Tops Estimate, Contraction In Manufacturing Worsens: &#8216;Reacceleration Of Inflation&#8217;</a>
Hunterbrook operates under two different arms:&nbsp;Hunterbrook Media&nbsp;and&nbsp;Hunterbrook Capital. The former is a media outlet publishing investigative and global reporting. The latter arm is a hedge fund, betting on or against some of the stocks on which it reports. Hunterbrook Capital noted that it is short Winnebago and LCI Industries based on Hunterbrook Media&#8217;s reporting. 
WGO Price Action: Winnebago shares were down 4.46% at $56.747 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40942923/short-seller-targets-verint-systems-stock-as-ai-threat-emerges-the-future-is-certainly-not-verint">Short Seller Targets Verint Systems Stock As AI Threat Emerges: &#8216;The Future Is Certainly Not Verint&#8217;</a></li>
</ul>
Photo: courtesy of Winnebago.

Short Sellers

Short Ideas

Cracks Across Winnebago? RV Stock Slides As Short Seller Warns Of 'Widespread Frame Failure'

Raymond James analyst Brian MacArthur maintains Lithium Royalty (TSX:<a class="ticker" href="https://www.benzinga.com/stock/LIRC#TSX">LIRC</a>) with a Outperform and lowers the price target from C$12 to C$10.

TSX:LIRC

Raymond James Maintains Outperform on Lithium Royalty, Lowers Price Target to C$10

Raymond James analyst Brian MacArthur maintains Hudbay Minerals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/HBM#TSX">HBM</a>) with a Outperform and raises the price target from C$14 to C$16.

TSX:HBM

Raymond James Maintains Outperform on Hudbay Minerals, Raises Price Target to C$16

JP Morgan analyst Matthew Boss maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Neutral and lowers the price target from $83 to $80.

JP Morgan Maintains Neutral on Nike, Lowers Price Target to $80

Allison Transmission (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) has outperformed the market over the past 10 years by 1.12% on an annualized basis producing an average annual return of 12.31%. Currently, Allison Transmission has a market capitalization of $7.93 billion. 
Buying $1000 In ALSN: If an investor had bought $1000 of ALSN stock 10 years ago, it would be worth $3,127.24 today based on a price of $90.97 for ALSN at the time of writing.
<h3>Allison Transmission's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727105417_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALSN

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,100 Today

Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 15 years by 6.46% on an annualized basis producing an average annual return of 18.32%. Currently, Cigna has a market capitalization of $99.13 billion. 
Buying $1000 In CI: If an investor had bought $1000 of CI stock 15 years ago, it would be worth $12,278.75 today based on a price of $354.59 for CI at the time of writing.
<h3>Cigna's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727105412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $12,000 Today

CNS Pharmaceuticals announces pricing of registered direct offering and concurrent private placement

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Thursday and we have breakdowns of all the latest news sending shares higher and lower this morning!



Moving stocks this morning are share sales, a new order, a closed public offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Blue Star Foods (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsfc-stock-quote/">BSFC</a>) stock is rocketing more than 67% alongside heavy pre-market trading.</li>



<li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) shares are surging over 67% after UBS Group AG (NYSE:<a href="https://investorplace.com/stock-quotes/ubs-stock-quote/">UBS</a>) <a href="https://www.benzinga.com/news/24/07/39725326/ev-maker-volcons-stock-skyrockets-over-70-in-pre-market-following-ubs-groups-buy-sell-transactions">bought and sold shares</a>.</li>



<li>CNS Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cnsp-stock-quote/">CNSP</a>) stock is soaring more than 51% alongside strong early morning trading.</li>



<li>MingZhu Logistics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ygmz-stock-quote/">YGMZ</a>) shares are gaining over 42% with strong pre-market trading today.</li>



<li>Actelis Networks (NASDAQ:<a href="https://investorplace.com/stock-quotes/asns-stock-quote/">ASNS</a>) stock is heading more than 30% higher on a <a href="https://www.nasdaq.com/press-release/actelis-receives-260000-order-major-mid-atlantic-us-county-traffic-system">traffic system order</a>.</li>



<li>Phoenix Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/pev-stock-quote/">PEV</a>) shares are increasing over 18% despite a lack of news this morning.</li>



<li>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) stock is climbing more than 17% as it <a href="https://investorplace.com/2024/07/why-is-kazia-therapeutics-kzia-stock-up-300-today/">continues a recent rally</a>.</li>



<li>Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) shares are rising close to 16% with heavy early morning trading.</li>



<li>Staffing 360 Solutions (NASDAQ:<a href="https://investorplace.com/stock-quotes/staf-stock-quote/">STAF</a>) stock is jumping over 13% on Thursday without any clear news.</li>



<li>Naas Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/naas-stock-quote/">NAAS</a>) shares are up 13% as part of an ongoing rally.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>TuanChe (NASDAQ:<a href="https://investorplace.com/stock-quotes/tc-stock-quote/">TC</a>) stock is plummeting more than 33% without any apparent news this morning.</li>



<li>Warrantee (NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) shares are diving over 27% on Thursday.</li>



<li>Inspire Veterinary (NASDAQ:<a href="https://investorplace.com/stock-quotes/ivp-stock-quote/">IVP</a>) stock is tumbling more than 26% after <a href="https://www.nasdaq.com/press-release/inspire-veterinary-partners-announces-closing-6-million-public-offering-2024-07-10">closing a public offering</a>.</li>



<li>Quhuo (NASDAQ:<a href="https://investorplace.com/stock-quotes/qh-stock-quote/">QH</a>) shares are taking an over 19% beating after a recent rally.</li>



<li>Cingulate (NASDAQ:<a href="https://investorplace.com/stock-quotes/cing-stock-quote/">CING</a>) stock is sliding more than 18% following a surprise rally yesterday.</li>



<li>Next Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxtt-stock-quote/">NXTT</a>) shares are dropping over 16% on Thursday morning.</li>



<li>Janover (NASDAQ:<a href="https://investorplace.com/stock-quotes/jnvr-stock-quote/">JNVR</a>) stock is decreasing more than 15% <a href="https://www.nasdaq.com/press-release/janovers-new-insurtech-platform-launches-do-liability-insurance-publicly-traded">after climbing higher yesterday</a>.</li>



<li>Zapp Electric Vehicles (NASDAQ:<a href="https://investorplace.com/stock-quotes/zapp-stock-quote/">ZAPP</a>) shares are slipping over 14% as it <a href="https://investorplace.com/2024/07/why-is-zapp-electric-vehicles-zapp-stock-down-25-today/">continues to retreat</a>.</li>



<li>Telesis Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/tbio-stock-quote/">TBIO</a>) stock is dipping nearly 14% after a similar rise yesterday.</li>



<li>SAI.TECH Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/sai-stock-quote/">SAI</a>) shares close out our pre-market stock movers down more than 13% <a href="https://www.nasdaq.com/press-release/saitech-announces-mou-signings-heatnuc-targeting-nuclear-and-smr-markets-middle-east">following a rally yesterday</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-july-11th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

CNS Pharmaceutical files for 2.36M offering of common stock

An update from CNS Pharmaceuticals (CNSP) is now available. CNS Pharmaceuticals, Inc. has secured an exclusive license from Cortice Biosciences, In...

CNS Pharmaceuticals Expands Portfolio with Strategic Licensing Deal

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
CNS Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cnsp-stock-quote/">CNSP</a>) stock is heading lower on Tuesday after the clinical-pharmaceutical company <a href="https://finance.yahoo.com/news/cns-pharmaceuticals-expands-pipeline-license-110000505.html">announced an expansion to its pipeline</a>.



CNS Pharmaceuticals has acquired an exclusive license and the intellectual property rights to TPI 287. This is a potential blood-brain barrier permeable microtubule inhibitor in development to treat Glioblastoma.



John Climaco, CEO of CNS Pharmaceuticals, said the following about the news.




&ldquo;For years, our team has searched for another drug candidate with the same high level of human data-supported therapeutic potential in GBM as Berubicin. The in-licensing of TPI 287 is a transformational step forward and we are prepared for the next stage to execute our vision of CNS Pharmaceuticals being the leading biopharma company developing drugs for this devastating and currently inescapably fatal disease.&rdquo;




<h2>Why This Affects CNSP Stock</h2>



The surprising news here is how the company acquired the license and rights. Rather than paying for them with cash, the company issued 616,698 shares of CNSP stock to cover the deal. It issued these shares to TPI 287 maker Cortice.



Investors aren&rsquo;t pleased about this news with it dropping shares of CNSP stock by 69.2% as of Tuesday afternoon. The stock is also down 99.5% since the start of the year.



There are even more stock market stories traders are going to want to read about today!



We have all of that ready with our dive into the latest stock market news on Tuesday! Among that is Georgia Rep. Marjorie Taylor Greene stock buys, the latest on 2U&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/">TWOU</a>) stock&nbsp;and more. All of this info is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/marjorie-taylor-greene-doubles-down-on-ai-boom-with-new-buys/">Marjorie Taylor Greene Doubles Down on AI Boom With New Buys</a></li>



<li><a href="https://investorplace.com/2024/07/2u-twou-stock-continues-to-surge-in-bankruptcy-rally/">2U (TWOU) Stock Continues to Surge in Bankruptcy Rally</a></li>



<li><a href="https://investorplace.com/2024/07/a-potential-stock-market-crash-trigger-looms-on-july-31/">A Potential Stock Market Crash Trigger Looms on July 31</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-cns-pharmaceuticals-cnsp-stock-down-69-today/">Why Is CNS Pharmaceuticals (CNSP) Stock Down 69% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is CNS Pharmaceuticals (CNSP) Stock Down 69% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
A Microsoft (NASDAQ:<a href="https://investorplace.com/stock-quotes/msft-stock-quote/">MSFT</a>) Office outage has workers annoyed as its causing problems with them being able to use the company&rsquo;s services.



This newest outage is affecting Microsoft Office and the company&rsquo;s <a href="https://x.com/MSFT365Status/status/1818267438435147865">Microsoft 365 services and features</a>. The company is working to resolve these issues and is advising users to track the outage status from the admin center.



Unfortunately, many users on X are reporting that they can&rsquo;t even access the admin center due to the outage. That resulted in Microsoft&rsquo;s Azure Services support account chiming in. It noted that there are also issues with its service that may be hindering users.



Here&rsquo;s what Mircosoft said about the problems in a post on X.




&ldquo;We&rsquo;ve applied mitigations and rerouted user requests to provide relief. We&rsquo;re monitoring the service to confirm resolution and further information can be found at <a href="https://status.cloud.microsoft" title="https://status.cloud.microsoft">https://status.cloud.microsoft</a> or under MO842351 in the admin center.&rdquo;




<h2>Microsoft Office Outage: What Happens Next?</h2>



It looks like the problems are clearly on Microsoft&rsquo;s end. That means there&rsquo;s not much users can do until the company sorts the matter out. Those looking for further updates can find them under the MO842351 ticker in the admin center, so long as they can get to it with the ongoing outage.



It&rsquo;s also worth noting that this comes not too long after <a href="https://www.bloomberg.com/news/articles/2024-07-30/microsoft-reports-outage-of-office-applications-and-services?embedded-checkout=true">another outage affected Windows computers</a>. Granted, that one was the fault of CrowdStrike (NASDAQ:<a href="https://investorplace.com/stock-quotes/crwd-stock-quote/">CRWD</a>) pushing out a bad update to users of Microsoft&rsquo;s operating system.



Investors looking for more of the biggest stock market stories today are in luck!



We have all of the hottest stock market news traders need to know about on Tuesday! That includes everything happening with Cassava Sciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sava-stock-quote/">SAVA</a>), SoundHound AI&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/soun-stock-quote/">SOUN</a>) and CNS Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cnsp-stock-quote/">CNSP</a>) stock today. All of that info is ready to go at the links below!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/sava-stock-cassava-sciences-extends-simufilam-trials-as-much-as-36-months/">SAVA Stock: Cassava Sciences Extends Simufilam Trials as Much as 36 Months</a></li>



<li><a href="https://investorplace.com/2024/07/soun-stock-alert-soundhound-expands-ai-rollout-with-stellantis/">SOUN Stock Alert: SoundHound Expands AI Rollout with Stellantis</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-cns-pharmaceuticals-cnsp-stock-down-69-today/">Why Is CNS Pharmaceuticals (CNSP) Stock Down 69% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/microsoft-office-outage-microsoft-investigates-applications-services-issue/">Microsoft Office Outage: Microsoft Investigates Applications, Services Issue</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Microsoft Office Outage: Microsoft Investigates Applications, Services Issue

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
SoundHound AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/soun-stock-quote/">SOUN</a>) stock is in the news Tuesday as the company is expanding its artificial intelligence (<a href="https://investorplace.com/stock-quotes/ai-stock-quote/">AI</a>) rollout <a href="https://finance.yahoo.com/news/soundhound-ai-rolls-voice-assistant-130300356.html">via a deal</a> with Stellantis (NYSE:<a href="https://investorplace.com/stock-quotes/stla-stock-quote/">STLA</a>).



With this collaboration, Alfa Romeo and Citro&euml;n will start adopting SoundHound AI&rsquo;s voice assistant. This includes vehicles sold in several European markets. The company&rsquo;s AI assistant is powered by ChatGPT.



SoundHound AI notes that with this integration, users will get live assistance while driving their vehicles. That includes the ability to ask for directions, popular nearby attractions and more.



Michael Zagorsek, COO of SoundHound AI, said the following about the news.




&ldquo;Drivers are still uncovering new and exciting uses for this highly capable, AI-driven voice technology. As we enter a new era for the vehicle cockpit, SoundHound is constantly pushing to deliver elite products that automakers trust and drivers love.&rdquo;




<h2>What This Does for SOUN Stock Today</h2>



SOUN stock is getting a 1.3% boost on Tuesday alongside this news. That has more than 13 million shares traded, as compared to a daily average of about 26.3 million units. Investors will also note that SOUN shares are up 132.8% since the start of the year.



We have all of the biggest stock market stories that traders are going to want to read about today!



That includes our coverage of all the latest stock market news available on Tuesday! A few examples of that is what&rsquo;s happening with shares of CNS Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cnsp-stock-quote/">CNSP</a>) stock, Georgia Rep. Marjorie Taylor Greene stock buys and why 2U&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/">TWOU</a>) stock is up today. All of this news is good to go at the links below!



<h2>More Tuesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-cns-pharmaceuticals-cnsp-stock-down-69-today/">Why Is CNS Pharmaceuticals (CNSP) Stock Down 69% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/marjorie-taylor-greene-doubles-down-on-ai-boom-with-new-buys/">Marjorie Taylor Greene Doubles Down on AI Boom With New Buys</a></li>



<li><a href="https://investorplace.com/2024/07/2u-twou-stock-continues-to-surge-in-bankruptcy-rally/">2U (TWOU) Stock Continues to Surge in Bankruptcy Rally</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/soun-stock-alert-soundhound-expands-ai-rollout-with-stellantis/">SOUN Stock Alert: SoundHound Expands AI Rollout with Stellantis</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SOUN Stock Alert: SoundHound Expands AI Rollout with Stellantis

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
CNS Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cnsp-stock-quote/">CNSP</a>) just reported results for the second quarter of 2024.<ul><li>CNS Pharmaceuticals reported earnings per share of -$6.72.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cnsp-stock-earnings-cns-pharmaceuticals-for-q2-of-2024/">CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q2 2024

CNS Pharmaceuticals reports Q2 results

CNS Pharmaceuticals regains Nasdaq compliance

ASNS

BSFC

CING

JNVR

KZIA

MSFT

NAAS

NXTT

SAVA

SLRX

SOUN

STAF

STLA

TBIO

VLCN

WRNT

YGMZ

ZAPP

Screenshot 2024-02-26 at 8.44.39 PM

Biotech

General

GBM, One Of The Deadliest Cancers, Could Have New Hope With Novel Drug

Press Releases

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

Earnings

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

CNS Pharma

CNS Pharma (CNSP) Forecast

CNS Pharma (NASDAQ:CNSP) Stock, Quote.Headers.trade-ideas